BioSpace News Archive

Varian and the Cincinnati Children’s/University of Cincinnati Medical Center Proton Therapy Center, today announced clinical trial results from FAST-01 (FeAsibility Study of Flash Radiotherapy for the Treatment of Symptomatic Bone Metastases), the first clinical trial of ultra-high dose rate Flash therapy and the first-in-human experience of proton Flash.

Turn Biotechnologies, a cell rejuvenation company developing novel mRNA medicines to cure untreatable, age-related conditions, today presents interim pre-clinical data that demonstrates treating T cells with its proprietary technologies can significantly increase their ability to kill cancer.

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) announced today that it plans to release its financial results for the second quarter ended September 30, 2022, after the close of market on Thursday, October 27, 2022.

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will report its third quarter financial results on Thursday, November 3, 2022.

Gilead Sciences, Inc. announced the presentation of real-world results from the BICSTaR study, highlighting Biktarvy® as a generally well tolerated and efficacious regimen regardless of prior treatment and comorbidity status in people with HIV.

Scenic Biotech, a pioneer in the discovery of genetic modifiers developing therapeutics to treat severe diseases, announced the appointment of Jens Würthner, MD, PhD, as Chief Medical Officer.

BioNTech SE will announce its financial results for the third quarter 2022 on Monday, November 7th, 2022.

SeaSpine Holdings Corporation today announced that it will release third quarter financial results after the close of trading on Tuesday, November 1, 2022.

Lutris Pharma today announced that the California Institute of Regenerative Medicine (CIRM) has awarded company Founder and Chairman of the Board, Antoni Ribas , M.D., Ph.D., Professor of Medicine Medical Pharmacology at the University of California Los Angeles (UCLA), a $5.0 million grant to be used for the further development of Lutris Pharma’s LUT017 gel, a novel, small molecule inhibitor of BRAF, for skin regeneration and wound healing.

AbbVie (NYSE: ABBV) today announced that 26 abstracts across its gastroenterology portfolio will be presented at the American College of Gastroenterology (ACG) Annual Scientific Meeting, October 21-26, 2022, in Charlotte, N.C., and virtually.